Welcome to our dedicated page for NeuroMetrix news (Ticker: $NURO), a resource for investors and traders seeking the latest updates and insights on NeuroMetrix stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NeuroMetrix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NeuroMetrix's position in the market.
Rhea-AI Summary
NeuroMetrix, Inc. announced steps to enhance shareholder value, including the appointment of Joshua S. Horowitz as a new independent director with extensive investing and public company board experience. The company also terminated its at-the-market equity facility. These actions were taken following feedback from one of its largest shareholders, Ephraim Fields of Echo Lake Capital, with the goal of maximizing shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.63%
Tags
-
Rhea-AI Summary
NeuroMetrix, Inc. (NURO) announces a study showcasing DPNCheck's efficacy in detecting diabetic peripheral neuropathy. The study reveals high diagnostic performance using DPNCheck combined with CVR-R, with an area under the receiver operating curve of 0.88. The findings support the simplicity, ubiquity, reproducibility, and reliability of DPN diagnosis using DPNCheck.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.81%
Tags
-
Rhea-AI Summary
NeuroMetrix, Inc. (NURO) announces positive reception for Quell Fibromyalgia with over 2000 patients prescribed since launch. Doctors praise the medication-free, safe, and effective treatment option for fibromyalgia patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
Rhea-AI Summary
Echo Lake Capital urges Neurometrix, Inc. (NURO) to fire Chairman and CEO Shai Gozani due to the stock's 99% decline since IPO, Gozani's $10 million compensation, FTC charges, personal $4 million settlement, and dilution of NURO shares below net cash value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
-
Rhea-AI Summary
Echo Lake Capital's Ephraim Fields urges Neurometrix, Inc. to liquidate due to significant undervaluation, questioning the Board's commitment to shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.97%
Tags
-
Rhea-AI Summary
NeuroMetrix, Inc. (NURO) reported financial and business highlights for Q4 2023. Quell Fibromyalgia showed accelerated growth with new business development strategies. The company filed for FDA approval for Quell for chemotherapy induced peripheral neuropathy. However, pressure on the DPNCheck market due to changes in CMS regulations poses a challenge.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.26%
Tags
Rhea-AI Summary
NeuroMetrix, Inc. (NURO) will release its 2023 fourth quarter and year-end business and financial highlights on February 22, 2024. The company will conduct a conference call at 8:00 a.m. ET on the same day for participants to ask questions. Access to the call can be obtained by registering in advance. An audio-only webcast and financial statements will be available on the company's website. A replay of the call will also be accessible for one year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.57%
Tags
-
News
Rhea-AI Summary
NeuroMetrix, Inc. (NURO) announces a strategic review process to enhance growth and shareholder value. The company plans to explore various options, including marketing strategy changes, asset acquisition, asset sale, and strategic transactions. Ladenburg Thalmann & Co. is engaged as the financial advisor. The company aims to leverage opportunities for Quell neuromodulation technology and address Medicare Advantage risk adjustment changes affecting the DPNCheck business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.55%
Tags
-
Rhea-AI Summary
NeuroMetrix, Inc. (NURO) to Present at Emerging Growth Conference on January 10, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
Rhea-AI Summary
NeuroMetrix, Inc. (Nasdaq: NURO) presented data from a clinical trial of Quell wearable neuromodulation technology for Long COVID patients. The trial was conducted at Baylor College of Medicine in collaboration with C2SHIP, with Dr. Bijan Najafi as the principal investigator.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
NeuroMetrix, Inc.
Nasdaq:NURO
NURO Rankings
NURO Stock Data
8.79M
1.67M
16.03%
5.68%
0.57%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
WALTHAM
About NURO
neurometrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. the company maintains an active research effort and has several pipeline programs. the company is located in waltham, massachusetts and was founded as a spinoff from the harvard-mit division of health sciences and technology in 1996. for more information, please visit neurometrix.com. neurometrix markets the following products: quell® wearable pain relief technology™ quell is 100% drug free wearable technology that has changed the lives of people suffering with chronic pain. it combines clinical strength neurostimulation to treat pain with an easy-to-use app that helps people manage pain and reclaim their lives. quell is doctor recommended and designed for people with chronic back pain, arthritic pain, nerve pain, leg and foot pain, among other chronic pain conditions. quell launc